10 Biotechnology Stocks to Sell Now

10 Biotechnology Stocks to Sell Now

This week, 10 Biotechnology stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Prothena Corp. Plc (PRTA) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in sales growth and return on equity. For more information, get Portfolio Grader’s complete analysis of PRTA stock.

Slipping from a C to a D rating, BioSpecifics Technologies Corp. (BSTC) takes a hit this week. BioSpecifics Technologies Corp. is a biopharmaceutical company that has been involved in the development of injectable collagenase for multiple indications. The company also gets F’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of BSTC stock.

This week, FibroGen, Inc.’s (FGEN) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of FGEN stock.

Inotek Pharmaceuticals Corporation (ITEK) is having a tough week. The company’s rating falls from a B to a D. The company also gets F’s in earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ITEK stock.

ADMA Biologics, Inc. (ADMA) earns a D this week, moving down from last week’s grade of C. The company also gets F’s in free cash flow. For more information, get Portfolio Grader’s complete analysis of ADMA stock.

Medgenics, Inc. (MDGN) slips from a C to a D this week. Medgenics, Inc. is a biopharmaceutical company that develops therapeutic protein delivery technology for the treatment of a range of chronic diseases. The company also gets F’s in earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of MDGN stock.

This week, ZIOPHARM Oncology, Inc. (ZIOP) drops from a D to a F rating. ZIOPHARM Oncology, Inc. is a biopharmaceutical company that engages in the development and commercialization of small molecule and synthetic biology approaches to cancer therapies in the United States. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of ZIOP stock.

This is a rough week for Anthera Pharmaceuticals, Inc. (ANTH). The company’s rating falls to F from the previous week’s D. Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing anti-inflammatory therapeutics for cardiovascular diseases, lupus and other serious diseases. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ANTH stock.

Brainstorm Cell Therapeutics Inc.’s (BCLI) rating weakens this week, dropping to a D versus last week’s C. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of BCLI stock.

Curis, Inc. (CRIS) declines this week from a D to a F. Curis, Inc. is a drug discovery and development company that engages in the research and development of cancer therapeutics. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of CRIS stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/08/10-biotechnology-stocks-to-sell-now-3/.

©2019 InvestorPlace Media, LLC